Menarini Group
HR Business Partner, R&D (Senior Manager/Associate Director)
Menarini Group, New York, New York, us, 10261
Overview
Reporting to the Senior Director, HRBP, the HR Business Partner (HRBP), R&D serves both as a strategic and operational partner supporting the Oncology Global R&D business by providing comprehensive HR support and guidance to drive organizational effectiveness and achieve business objectives. This role will leverage 8+ years of experience in HR Business Partnering and HR Operations, within the biotech/pharmaceutical industry, including supporting biotech research and development, to deliver impactful solutions in talent management, employee engagement and relations, compensation, and organizational development. The ideal candidate will be a data-driven problem solver with strong analytical, communication, and influencing skills, capable of building effective relationships with employees at all levels.
Candidates should be within commuting distance to Menarini Stemline's NYC offices. Expected business travel and/or onsite requirements in NYC = 25%.
Responsibilities Business Partnership
Serve as a trusted advisor to leaders, providing strategic HR guidance and operational support aligned with business goals.
Proactively identify and address HR-related challenges and opportunities within assigned business units.
Coach leaders in various aspects of people management, including providing effective feedback and performance development.
Identify critical capabilities and lead initiatives to build a future-ready workforce in client areas, including supporting and enabling the integration of AI into key business processes.
Collaborate and assist HR Operations to deliver integrated HR solutions.
Talent Management & Development
Guide and assist with the identification of, and address, talent development needs, facilitating training and development initiatives.
Guide and assist in succession planning and talent pipeline development.
Partner with managers to assist with effective retention strategies.
Support performance management processes, including goal setting, performance reviews, and development planning.
Collaboration & Communication
Build and maintain strong relationships with employees at all levels of the organization.
Effectively communicate HR initiatives and programs to employees and managers.
Collaborate with cross-functional teams to achieve organizational goals.
Influence stakeholders to drive HR initiatives.
Play a key role with the promotion of our culture and overall engagement.
Employee Engagement & Employee Relations
Support managers in building and leading highly engaged and motivated teams
Provide both proactive, and where needed reactive, guidance and support to managers and employees on employee relations and performance matters, ensuring fair and consistent application of policies and procedures.
When needed, conduct thorough and impartial investigations into employee complaints and concerns, resolving issues in a timely and effective manner.
Partnering with Employment Counsel, mitigate risk by ensuring compliance with all applicable employment laws and regulations.
Qualifications
Bachelor's degree in Human Resources, Business Administration, or a related field.
Proven HRBP experience with Pharmaceutical/Biotech Research and Development (R&D) is required.
Start-up or small biotech experience is highly preferred.
Minimum of 8+ years of progressive HR experience, including HR Business Partner and HR Operations roles.
Experience in a high-growth, fast-paced, lean environment.
Willingness to roll up sleeves and find solutions to issues that arise.
Strong knowledge of HR principles, practices, and employment laws.
Demonstrated knowledge in talent management, employee relations, compensation, and organizational development.
Excellent analytical and problem-solving skills, with a focus on data integrity.
Strong influencing and communication skills, with the ability to build rapport and credibility at all levels.
Proficiency in HRIS systems –Workday. Google Products – Smartsheet, Docs, Slides and Sheets and Microsoft Office Suite – Excel, PowerPoint, Word, etc.
Ability to work independently and as part of a team in a fast-paced environment.
Desire to collaborate, learn, and grow.
Strong ethical standards and commitment to confidentiality.
Experience with Workday implementation.
Preferred Qualifications
SHRM-CP/SCP or PHR/SPHR certification.
Key Competencies
Strategic Thinking
Problem Solving
Influencing & Negotiation
Strong Communication (Written & Verbal)
Relationship Building
Data Analysis
Attention to Detail
Organizational Skills
Business Acumen.
Base Salary Ranges:
Senior Manager: $118,000-$153,000
Associate Director: $150,000-$190,000.
Menarini Stemline offers generous compensation and benefits packages, Fidelity 401(k) (with company match), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.
This position is classified as a corporate office position. In accordance with the New York employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely.
Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.
The Company Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.
The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.
Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.
Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).
Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.
Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.
Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.
Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.
In 2022, the company launched the CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.
Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.
It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.
#J-18808-Ljbffr
Candidates should be within commuting distance to Menarini Stemline's NYC offices. Expected business travel and/or onsite requirements in NYC = 25%.
Responsibilities Business Partnership
Serve as a trusted advisor to leaders, providing strategic HR guidance and operational support aligned with business goals.
Proactively identify and address HR-related challenges and opportunities within assigned business units.
Coach leaders in various aspects of people management, including providing effective feedback and performance development.
Identify critical capabilities and lead initiatives to build a future-ready workforce in client areas, including supporting and enabling the integration of AI into key business processes.
Collaborate and assist HR Operations to deliver integrated HR solutions.
Talent Management & Development
Guide and assist with the identification of, and address, talent development needs, facilitating training and development initiatives.
Guide and assist in succession planning and talent pipeline development.
Partner with managers to assist with effective retention strategies.
Support performance management processes, including goal setting, performance reviews, and development planning.
Collaboration & Communication
Build and maintain strong relationships with employees at all levels of the organization.
Effectively communicate HR initiatives and programs to employees and managers.
Collaborate with cross-functional teams to achieve organizational goals.
Influence stakeholders to drive HR initiatives.
Play a key role with the promotion of our culture and overall engagement.
Employee Engagement & Employee Relations
Support managers in building and leading highly engaged and motivated teams
Provide both proactive, and where needed reactive, guidance and support to managers and employees on employee relations and performance matters, ensuring fair and consistent application of policies and procedures.
When needed, conduct thorough and impartial investigations into employee complaints and concerns, resolving issues in a timely and effective manner.
Partnering with Employment Counsel, mitigate risk by ensuring compliance with all applicable employment laws and regulations.
Qualifications
Bachelor's degree in Human Resources, Business Administration, or a related field.
Proven HRBP experience with Pharmaceutical/Biotech Research and Development (R&D) is required.
Start-up or small biotech experience is highly preferred.
Minimum of 8+ years of progressive HR experience, including HR Business Partner and HR Operations roles.
Experience in a high-growth, fast-paced, lean environment.
Willingness to roll up sleeves and find solutions to issues that arise.
Strong knowledge of HR principles, practices, and employment laws.
Demonstrated knowledge in talent management, employee relations, compensation, and organizational development.
Excellent analytical and problem-solving skills, with a focus on data integrity.
Strong influencing and communication skills, with the ability to build rapport and credibility at all levels.
Proficiency in HRIS systems –Workday. Google Products – Smartsheet, Docs, Slides and Sheets and Microsoft Office Suite – Excel, PowerPoint, Word, etc.
Ability to work independently and as part of a team in a fast-paced environment.
Desire to collaborate, learn, and grow.
Strong ethical standards and commitment to confidentiality.
Experience with Workday implementation.
Preferred Qualifications
SHRM-CP/SCP or PHR/SPHR certification.
Key Competencies
Strategic Thinking
Problem Solving
Influencing & Negotiation
Strong Communication (Written & Verbal)
Relationship Building
Data Analysis
Attention to Detail
Organizational Skills
Business Acumen.
Base Salary Ranges:
Senior Manager: $118,000-$153,000
Associate Director: $150,000-$190,000.
Menarini Stemline offers generous compensation and benefits packages, Fidelity 401(k) (with company match), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.
This position is classified as a corporate office position. In accordance with the New York employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely.
Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.
The Company Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.
The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.
Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.
Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).
Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.
Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.
Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.
Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.
In 2022, the company launched the CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.
Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.
It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.
#J-18808-Ljbffr